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Myc stimulates cell cycle 
progression through the activation 
of Cdk1 and phosphorylation of p27
Lucía García-Gutiérrez1,6, Gabriel Bretones1,7, Ester Molina1, Ignacio Arechaga1, 
catherine Symonds3,8, Juan C. Acosta2, Rosa Blanco1, Adrián Fernández1, Leticia Alonso1, 
piotr Sicinski4, Mariano Barbacid3, David Santamaría5 & Javier León1*
Cell cycle stimulation is a major transforming mechanism of Myc oncoprotein. This is achieved through 
at least three concomitant mechanisms: upregulation of cyclins and Cdks, downregulation of the Cdk 
inhibitors p15 and p21 and the degradation of p27. The Myc-p27 antagonism has been shown to be 
relevant in human cancer. To be degraded, p27 must be phosphorylated at Thr-187 to be recognized 
by Skp2, a component of the ubiquitination complex. We previously described that Myc induces Skp2 
expression. Here we show that not only Cdk2 but Cdk1 phosphorylates p27 at the Thr-187. Moreover, 
Myc induced p27 degradation in murine fibroblasts through Cdk1 activation, which was achieved by 
Myc-dependent cyclin A and B induction. In the absence of Cdk2, p27 phosphorylation at Thr-187 was 
mainly carried out by cyclin A2-Cdk1 and cyclin B1-Cdk1. We also show that Cdk1 inhibition was enough 
for the synthetic lethal interaction with Myc. This result is relevant because Cdk1 is the only Cdk strictly 
required for cell cycle and the reported synthetic lethal interaction between Cdk1 and Myc.
Progression through the cell cycle is controlled by a highly conserved family of serine/threonine protein kinases. 
These kinases are heterodimers that consist of a catalytic subunit, the cyclin-dependent protein kinase (Cdk) and 
a regulatory subunit, the cyclin, which is required for the Cdk to become active. Although Cdks and cyclins are 
large protein families, Cdk1, 2, 4 and 6 and A, B, E, D-type cyclins are identified as the major regulators of the 
cell cycle1. Systematic knockout of Cdk loci in the mouse germline has shown that Cdk22,3, Cdk44,5 and Cdk66 are 
not essential for cell cycle progression of most cell types, although loss of each of these Cdks results in particular 
developmental defects. Moreover, concomitant loss of the genes of interphase Cdks does not result in a general 
disturbance of the cycle in most cell types, being Cdk1 alone sufficient and essential to drive the entire cycle1,7.
Myc (also called c-Myc) is an oncogenic transcription factor that belongs to the helix-loop-helix/leucine zip-
per family of proteins. Myc-mediated transcriptional activation depends on its interaction with Max, another 
helix-loop-helix transcription factor. Myc-Max heterodimers bind to DNA sequences known as E-boxes within 
the regulatory regions of their target genes and recruit transcriptional coactivators. Nevertheless, Myc has also 
the ability to repress gene transcription through less known mechanisms (for reviews see8–10). Myc is found 
deregulated in nearly half of human solid tumors and leukemia, and appears frequently associated with tumor 
progression11–13.
Induction of cell proliferation by promoting G1 to S-phase transition during cell cycle progression is one of 
Myc’s best characterized functions, a feature linked to its pro‐oncogenic activity. Indeed, enforced Myc expression 
in quiescent cells is sufficient to mediate cell cycle entry. At least three major mechanisms account for this: (i) the 
transcriptional activation of genes required for cell cycle progression, including a number of cyclins (D2, A, E); 
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(ii) the repression of CDKN2B (p15) and CDKN1A (p21) genes and (iii) the degradation of CDKN1B/p27KIP1 
(p27 here after) cell cycle inhibitor (reviewed in14).
The well-established Myc-p27 antagonism is one of the major mechanisms of Myc-mediated tumorigenic 
function. p27 is a Cdk inhibitor found downregulated in proliferating cells and in many tumors. Cyclin E-Cdk2 
is considered p27’s primary target15,16, although other targets rather than Cdk2 have been proposed17. The ability 
of Myc to overcome the p27-mediated proliferative arrest has been demonstrated not only in cell culture18,19, 
but also in animal carcinogenesis models20. This antagonistic effect of Myc on p27 is mediated through several 
concomitant mechanisms: (i) Myc induces cyclin D2 and Cdk4, which sequester p27 allowing cyclin E-Cdk2 
activation21,22; (ii) Myc induces expression of Cullin 1 (Cul1)23 and Cks124, both components of the SCFSKP2 com-
plex and (iii) we showed that Skp2, the p27-recognizing subunit of the SCFSKP2 ubiquitin ligase complex is a Myc 
target gene25. Moreover, Skp2 has been considered to have oncogenic potential and is found overexpressed in 
many human tumors26,27.
Previous studies indicated that p27 must be phosphorylated at Thr-187 to be recognized by the SCFSKP2 ubiq-
uitin ligase complex, and thus being efficiently ubiquitinated and targeted for proteasome-mediated degrada-
tion28,29. In this work, we studied the mechanism of Myc-mediated phosphorylation of p27 independently of 
Cdk2 activity. Through genetic analysis based on loss of function of Cdk1 and Cdk2 along with conditional 
Myc expression, we show here the pivotal role of Cdk1 on p27 phosphorylation and its potential relevance for 
Cdk1-based synthetic lethal approaches to control Myc in cancer.
Results
Myc induces phosphorylation of p27 mediated by Cdk1 and Cdk2 in human leukemia cells. 
Previous results in our laboratory in a human myeloid leukemia cell line K562 have shown that Myc´s ability to 
promote cell cycle progression depends on the reduction of p27 (p27KIP1, CDKN1B) protein levels19. We used 
a K562 derivative cell line, called Kp27MER, which contains a Zn2+- inducible p27 construct and the chimeric 
protein Myc-ER, which is constitutively expressed but only active in presence of 4-hydroxi-tamoxifen (4HT). In 
this model, induction of p27 lead to arrested proliferation, while Myc-ER activation by 4HT induced p27 phos-
phorylation at the Thr-187 and partially rescued the proliferative state19,25. We first confirmed that concomitant 
induction of p27 and Myc-ER activation resulted in decreased p27 levels, as expected (Fig. 1a). p27 induction 
decreased cyclin A2 expression and this was counteracted by concomitant activation of Myc-ER, consistently with 
the proliferation arrest exerted by p27 and its partial rescue by Myc. These changes were not observed in parental 
K562 cells (Supplementary Fig. S1a). Downregulation of endogenous Myc upon 4HT addition is a marker of the 
Myc-ER activation (Fig. 1a). Expression of cyclins B and E, and Cdk1 and Cdk2 upon those conditions are also 
shown and did not show major changes (Fig. 1a). The decrease of p27 in Kp27MER is linked to Myc-mediated 
phosphorylation of p2725. Thus, we investigated whether Myc-mediated p27 phosphorylation was specific for 
cyclin E-Cdk2 complexes as previously reported30,31 or if other cyclin-cdk complexes could be involved due to 
their redundancy.
Upon high p27 levels (i.e., by addition of Zn2+ in our model), Cdk1 and Cdk2 complexes are inhibited as 
expected and demonstrated by in vitro kinase assays using His-p27 as substrate (Fig. 1b). However, activation 
of Myc-ER under these conditions rescued the impaired kinase activity over p27 of, not only Cdk2, but also 
Cdk1 (Fig. 1b). To investigate which cyclin regulates Cdk1/2 kinase activity upon Myc-ER activation, cyclins A2, 
B1 and E were immunoprecipitated (Supplementary Fig. S1b) and subjected to in vitro kinase assays under the 
same conditions as before. The results showed that the kinase activity of the three immunocomplexes was low 
in cells expressing p27 (i.e., treated with Zn2+) but was dramatically enhanced upon Myc activation (i.e., with 
4HT) (Fig. 1c). However, differences are found within the interaction affinities between certain cyclins and cdks. 
These results suggest that not only Cdk2 but also Cdk1 could phosphorylate p27 at the Thr-187 promoting its 
degradation (in agreement with the well-known redundancy of cyclin-cdk complexes) and that Myc regulates 
such activity.
Myc stimulates proliferation and p27 degradation in cells lacking Cdk2 or cyclin E-associated 
kinase activity. It is known that p27 levels within the cell are mainly controlled by cyclin E-Cdk2, and that 
Myc mainly relies on cyclin E-Cdk2 activity to phosphorylate p27. Thus, and in agreement with the fact that 
Cdk1 could substitute Cdk2 in such task, we set out a series of experiments to elucidate the potential role of Cdk1 
on Myc-dependent stimulation of cell cycle progression independently of Cdk2 activity. First, we compared the 
effect of Myc enforced expression on the proliferation of wild-type MEFs and MEFs lacking either cyclin E or 
Cdk2 expression (wild type, Cdk2−/− and Ccne−/− MEFs respectively). Myc enforced expression was achieved by 
lentiviral transduction and confirmed by western blot (Fig. 2a). Comparison between the proliferation rates of 
Cdk2−/− cells and Ccne−/− cells with that of their overexpressing Myc counterparts showed that exogenous Myc 
overexpression increases proliferation rates of Cdk2−/− as well as that of Ccne−/− MEFs (Fig. 2b).
To explore the mechanisms through which Myc increases cell proliferation independently of cyclin E-Cdk2 
complexes, we first studied the expression of cyclins and Cdks involved in cell cycle progression in Cdk2−/− 
MEFs. The results showed that in Myc-overexpressing cells, Cdk1, Cdk4, cyclin A2, cyclin B1 and cyclin E2 
expression were higher than in control Lv141 cells at both, mRNA and protein levels (Fig. 2c). Cell starvation 
followed by serum stimulation of Cdk2−/− MEFs revealed that upon Myc overexpression, the induction of cyclins 
at the mRNA level was accelerated in time when compared with control cells infected with the empty viral vector 
(Lv141) and the cyclin expression levels achieved were higher (Fig. 2d). Indeed, basal mRNA expression levels 
were already higher after starvation in Myc-overexpressing cells compared to controls (Fig. 2d). Consistently, 
we found that retinoblastoma was hyperphosphorylated in Myc-overexpressing cells (Fig. 2e). In summary, we 
showed that Myc overexpression induced proliferation in cells deficient in either cyclin E or Cdk2 and this was 
accompanied with an increase in cyclin A2 and B1 expression, as described in other models32–35.
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The main degradation pathway of p27 has been described to rely on Cdk2 kinase activity. Due to the oppo-
site correlation between p27 and Myc in proliferating and tumor cells, we analyzed whether in the absence of 
Cdk2 kinase activity Myc was able to reduce p27 protein levels. First, p27 levels were analyzed in Cdk2−/− MEFs 
expressing the chimeric protein Myc-ER (termed Cdk2−/− MER MEFs). Cells were grown until confluence to 
enforce p27 accumulation and then treated with 4HT to activate Myc-ER. Activation of Myc-ER was accompa-
nied by increased levels of Cdk1 and Skp2, while p27 protein levels were reduced (Fig. 3a). The increase in Skp2 
levels is consistent with the reduction of p27 and Myc activation, as Skp2 is a direct Myc target gene responsible 
of the recognition of p27 to be further degraded25. Thus, to investigate the effect of Myc on p27 stability in the 
absence of Cdk2, Cdk2−/− Myc MEFs and their corresponding control Cdk2−/− Lv141 MEFs were transfected 
with a p27-YFP construct and treated with cycloheximide, a protein synthesis inhibitor. After different periods 
of cycloheximide treatment, p27 protein levels were analyzed by western blot (Fig. 3b) and quantified (Fig. 3C). 
Myc protein levels (a well-known short half-life protein) are shown as a technical control of the efficacy of the 
cycloheximide treatment (Supplementary Fig. S2). The results showed that p27 protein levels decreased faster in 
cells overexpressing Myc than in control cells, suggesting that Myc affects p27 stability in the absence of Cdk2. 
In summary we have shown that Myc was able to promote proliferation and p27 degradation in Cdk2−/− MEFs.
Myc-mediated degradation of p27 can be explained by Myc induction of Skp225, an effect that we have 
confirmed in MEFs (Fig. 3b). However, to be recognized by Skp2, p27 must be phosphorylated at Thr-187, a 
Figure 1. Myc-mediated induction of p27 phosphorylation in leukemia cells. (a) Kp27MER cells were treated 
with 50 µM Zn2+ and 200 nM 4HT for 24 hours as indicated to induce ectopic p27 expression and Myc-ER 
activation. Myc, Myc-ER, cyclins A2, B1 and E, Cdk1, Cdk2 and p27 levels are shown. Actin levels were used 
as loading control. (b) Immunoprecipitated Cdk2 (upper panel) and Cdk1 (lower panel) complexes from 
Kp27MER cells treated with Zn2+ and 4HT for 12 hours as indicated and subjected to in vitro kinase assays with 
His-p27 as substrate. Levels of Cdk1 and Cdk2 in immunoprecipitates are also shown. (c) Immunoprecipitated 
cyclin B1, cyclin A2, cyclin E complexes from Kp27MER treated with Zn2+ and 4HT for 12 hours as indicated 
and subjected to in vitro kinase assays using His-p27 as substrate. Levels of Cdk1 and Cdk2 present in cyclin 
A2, cyclin B1 and cyclin E are also shown. Asterix (*) in kinase assays shows light chain of the antibody from 
immunoprecipitation Signal densitometry quantification of the kinase assays are shown below each lane. Kinase 
buffer with His-p27 was used as negative control (No IP).
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phosphorylation that has been reported to be mediated by cyclin E/A-Cdk230,31. We have shown here that Cdk1 
could phosphorylate p27 in human leukemia cells (Fig. 1b). Indeed, previous reports demonstrated that Cdk2−/− 
mice showed phosphorylated p27 at the Thr-1873 and that cyclin B-Cdk1 could phosphorylate p27 in vitro but in 
a lesser extent when compared with Cdk2 complexes36. Thus, we hypothesized that in the absence of Cdk2, Myc 
would induce p27 phosphorylation through Cdk1 activation.
To confirm this hypothesis, we first explored p27 phosphorylation by Cdk1 at the Thr-187 in Cdk2−/− MEFs. 
Thus, Cdk1 immunocomplexes were prepared from Cdk2−/− Myc MEFs and Cdk2−/− Lv141 MEFs and subjected 
to in vitro kinase assays to test their activity on p27 at the Thr-187 and whether Myc increases it. The amount of 
immunoprecipitated Cdk1 was assayed by western blot (Fig. 4a right panel). As shown in Fig. 4a left panel, Cdk1 
immunocomplexes efficiently phosphorylated p27. Cdk1-mediated phosphorylation of p27 resulted higher in 
immunocomplexes obtained from Cdk2−/− Myc cells when compared to control cells. Besides, treatment of the 
Figure 2. Proliferation rates of Myc-transduced Cdk2−/− and Ccne−/− MEFs. (a) Myc transduction of parental, 
Cdk2−/− and Ccne−/− MEFs analyzed by western blot. Actin levels were used as loading control. (b) Proliferation 
curves of wild-type (wt), Cdk2−/− and Ccne−/− MEFs stably transduced with a constitutive Myc vector 
compared with controls (Lv141). Data is shown as total number of cells per condition. Error bars represent ± SD 
of two independent experiments. (c) Left panel: mRNA expression of Cdk1, Ccna2, Ccnb1 and Ccne2 genes 
analyzed by RT-PCR and normalized to β-actin levels. Error bars represent ± SD of at least two independent 
experiments. Right panel: Protein expression of Myc, cyclin A2, cyclin B1, Cdk1 and Cdk4 analysed by western 
blot. Actin levels were used as loading control. (d) mRNA expression of Ccne2, Ccna2 and Ccnb1 of Cdk2−/− 
Lv141 MEFs and Cdk2−/− Myc MEFs in either serum-starved (0 h) or serum-stimulated (18–24 h) conditions 
determined by RT-PCR and normalized against the maximum expression of each cyclin within both cell lines. 
Error bars represent ± SD of five independent experiments. Statistical analysis: 2 way-ANOVA.*P < 0.033 and 
***P < 0.001. (e) Phosphorylation of Rb protein analysed by western blot in Cdk2−/− Lv141 and Cdk2−/− Myc 
MEFs using a phospho-specific antibody for pRb.
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immunocomplexes with the Cdk1 inhibitor purvalanol A led to a decrease in p27 phosphorylation levels com-
pared to untreated ones.
To verify Cdk1-mediated p27 phosphorylation, we transfected Cdk2−/− Myc MEFs and Cdk2−/− Lv141 MEFs 
with an inactive mutant of Cdk1 lacking kinase activity (Cdk1D146N, Cdk1DN herein after) and we performed in 
vitro kinase assays. The empty vector (EV) and wild-type Cdk1 were used as controls. The transfected wild-type 
Cdk1 and Cdk1DN were tagged with an HA epitope, which served to detect the exogenous Cdk1 (Fig. 4b). Due to 
the poor efficiency of the anti-HA antibody to immunoprecipitate our HA-tagged Cdk1 constructs, Cdk1 immu-
nocomplexes were prepared with an anti-Cdk1 antibody followed by in vitro p27 phosphorylation assay. The 
exogenous immunoprecipitated Cdk1 was detected by western blot with anti-HA antibody (Fig. 4c). The kinase 
assays showed that overexpression of Cdk1wt in Cdk2−/− Myc MEFs led to higher phospho-p27 levels while the 
Cdk1DN form did not show this effect when compared with the empty vector. Furthermore, overexpression of 
either wild-type Cdk1 or Cdk1DN showed no major differences in p27 phosphorylation compared with the empty 
vector in Cdk2−/− Lv141 MEFs (Fig. 4d). This suggests that the limiting factor in p27 phosphorylation is not Cdk1 
but cyclin levels, as higher Cdk1 protein levels do not have any effect unless Myc is overexpressed.
The above results demonstrated that Myc stimulates the phosphorylation of p27 mediated by Cdk1. Next, we 
investigated the cyclin partner of Cdk1 in this function. For this purpose, we used cells deficient in cyclin E1/
E2. Both Cdk1 and Cdk2 were able to phosphorylate p27 in vitro in the absence of cyclin E (Fig. 5a). We silenced 
cyclin A2 expression in Ccne−/− MEFs by shRNA lentiviral transduction (Supplementary Fig. S3a). Both Cdk1 
and Cdk2 immunocomplexes showed reduced in vitro kinase activity on p27 (Fig. 5a). These results show that 
Cdk1-mediated phosphorylation of p27 is regulated, in part, by cyclin A2, a function unreported so far. However, 
Cdk1 activity was affected in a lesser extent by cyclin A2 downregulation than that of Cdk2, suggesting that cyclin 
B could be also regulating Cdk1-mediated p27 phosphorylation in these cells, consistently with results previously 
reported37. We also tested whether Myc increased p27 phosphorylation in this model. Ccne−/− MEFs were trans-
duced with a Myc-IRES-GFP construct or the empty vector (Lv141) and sorted by GFP expression. Cdk1 or cyclin 
A2 were immunoprecipitated (Supplementary Fig. S3B) and the in vitro kinase assays showed that Myc overex-
pression increased Cdk1-mediated p27 phosphorylation (Fig. 5b), as well as cyclin A2-associated kinase activity 
on p27 (Fig. 5c). Total levels of cyclin A2 and Cdk1 were assessed by western blot (Supplementary Fig. S3a). 
Purvalanol A treatment abolished p27 phosphorylation in all cases. Altogether the results showed that both Cdk1 
and Cdk2 were able to phosphorylate p27 at the Thr-187 in a cyclin E independent manner, suggesting that, in 
addition to cyclin A-Cdk2, cyclin A-Cdk1 and/or cyclin B-Cdk1 might be responsible for p27 phosphorylation.
Next, we tested the potential role of cyclin A2 as Cdk1 partner in Lv141 and Myc-overexpressing Cdk2−/− 
MEFs. Kinase assays of cyclin A2 complexes from Cdk2−/− MEFs led to p27 phosphorylation and was increased 
by Myc. Besides, treatment of the complexes with purvalanol A decreased p27 phosphorylation (Fig. 6a). 
Furthermore, we analyzed the requirement of cyclin A2 in this function. Knocking down cyclin A2 in Cdk2−/− 
Lv141 and Cdk2−/− Myc MEFs was achieved by shRNA lentiviral transduction (Fig. 6b). In order to test the 
efficiency of cyclin A2 knock down, we performed in vitro kinase assays of cyclin A2 upon these conditions and 
we found that downregulation of cyclin A expression lead to a reduction in p27 phosphorylation as expected 
Figure 3. Myc-mediated degradation of p27. (a) Protein levels of Myc, Skp2, Cdk1 and p27 of Cdk2−/− MER 
MEFs grown until confluence and treated with 500 nM of 4HT for 18 hours (overnight). Actin levels were used 
as loading control. (b) Protein stability of p27 in Cdk2−/− Lv141 and Cdk2−/− Myc MEFs transfected with a 
p27-YFP construct measured by western blot. Levels of p27-YFP were detected after 0, 0.5, 1 and 3 hours of 
cycloheximide treatment (30 µg/mL). Actin levels were used as loading control. (c) Densitometric quantification 
of p27 protein levels after cycloheximide treatment normalized to actin levels. Error bars represent ± SD of three 
independent experiments. Statistical analysis: T.test: *p < 0.1; **p < 0.05.
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(Supplementary Fig. S4). Furthermore, kinase assays showed that Myc overexpression resulted in increased 
Cdk1-mediated p27 phosphorylation, but cyclin A2 depletion did not affect it (Fig. 6c). These results showed 
that the increased kinase activity of Cdk1 did not depend only on the upregulation of cyclin A2 by Myc. Thus, 
we explored cyclin B1 as another potential regulator of Cdk1-mediated p27 phosphorylation induced by Myc. 
Immunoprecipitated cyclin B1 complexes from Cdk2−/− Lv141 MEFs were able to phosphorylate p27 in vitro, as 
expected, while Myc increased cyclin B1-associated kinase activity on p27. Moreover, downregulation of cyc-
lin A2 levels did not affect it (Fig. 6d). Interaction of Cdk1 with cyclins A2 and B1 in these cells is shown in 
Supplementary Fig. S5.
Myc induces proliferation and Cdk1-mediated p27 phosphorylation in triple knock out 
MEFs. As Cdks show redundant functions within the cells, we decided to use a triple knock out MEF cell line 
lacking Cdk2, Cdk4 and Cdk6 functional genes (Cdk2−/−; Cdk4−/−; Cdk6−/− MEFs, termed TKO MEFs herein 
after). This model would help to verify that Cdk1 was also responsible for the phosphorylation of p27 upon Myc 
expression. TKO MEFs were transduced with a Myc-IRES-GFP construct and GFP expressing cells were sorted. 
The resulting cell line was termed TKO-Myc MEFs.
First, comparison between TKO and TKO-Myc MEFs proliferation rates showed that Myc overexpressing 
cells grew much faster than parental cells (Fig. 7a), in agreement with an increase in the percentage of cells in 
S-phase (Fig. 7b; Supplementary Fig. S6a). Consistently, Cdk1, Ccna2, Ccnb1 and Ccne2 expression was elevated 
in cells overexpressing Myc at the mRNA (Fig. 7c) and protein level (Fig. 7d). Moreover, the expression of cyclins 
A2, B1 and E2 was not only higher in TKO-Myc than parental TKO MEFS but also induced earlier in time upon 
serum stimulation (Fig. 7e). This verifies the importance of Myc as a cell cycle regulator, even in cells whose cell 
cycle is only driven by Cdk1. In agreement, downregulation of exogenous Myc in TKO-Myc MEFs by shRNA 
transduction (Fig. 7f) lead to arrested cell proliferation (Fig. 7g) and reduced expression of Cdk1, Ccna2, Ccnb1 
and Ccne2 (Fig. 7h).
Figure 4. Cdk1 mediated phosphorylation of p27 at the Thr-187. (a) Left panel: In vitro kinase assay of Cdk1 
immunoprecipitated from Cdk2−/− Lv141 and Cdk2−/− Myc MEFs using His-p27 as substrate. Phosphorylation 
levels of p27 at the Thr-187 were detected using a phospho-specific antibody. Right panel: Levels of the 
immunoprecipitated Cdk1 assayed in the experiment of the left panel measured by western blot. (b) Total 
lysates from Cdk2−/− Lv141 and Cdk2−/− Myc MEFs transfected with empty vector (Ev) HA-Cdk1-wt (WT), 
HA-Cdk1-DN (DN) or non-transfected (NT). Total Cdk1 and exogenous Cdk1 are shown (anti-Cdk1 and 
anti-HA antibodies respectively). Actin levels were used as loading control. (c) Total Cdk1 immunoprecipitated 
from protein extracts showed in the left panel and immunoprecipitated exogenous Cdk1 levels measured with 
anti-HA. (d) Kinase activity of Cdk1 wild-type (WT) and Cdk1DN (DN) on Thr-187 of p27. Immunocomplexes 
were treated with 10 µM purvalanol A (Purv A) or vehicle (DMSO) in the kinase assays when indicated. Signal 
densitometry quantification of the kinase assays are shown below each lane. Unspecific IgGm was used as 
negative control for the specificity of the antibody used for immunoprecipitation.
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Since the only Cdk involved in cell cycle progression of TKO MEFs is Cdk1, we wondered whether Myc was 
able to induce Cdk1 kinase activity in these cells. We first investigated the presence of Cdk1-phosphorylated 
substrates using a phospho-specific antibody against the consensus amino acid sequence recognized and phos-
phorylated by Cdks. The results showed that Myc overexpression resulted in higher Cdk activity in TKO MEFs 
whereas downregulation of exogenous Myc levels in TKO-Myc MEFs lead to a decrease in total Cdk activity 
(Fig. 8a). Moreover, Myc overexpression in TKO MEFs induced Skp2 levels when compared with control TKO 
cells in the same extent as in other models. In agreement, knocking down ectopic Myc expression lead to a 
decrease in Skp2 levels (Fig. 8b), which is consistent with the results previously obtained using the Cdk2−/− MEFs 
cell line. Besides, Skp2 and p27 levels show opposite expression profiles upon Myc overexpression (Fig. 8c).
These results suggest that p27 proteasomal degradation mediated by the SCFSKP2 complex could be achieved 
even in the only presence of Cdk1. First, we verified that cells lacking Cdk2, Cdk4 and Cdk6 could efficiently 
phosphorylate p27 at the Thr-187 in TKO-Myc cells. TKO-Myc MEFs transfected with a p27-YFP construct 
showed phosphorylation at the Thr-187 of p27 (Fig. 8d). As control, TKO-Myc MEFs transfected with p27-YFP 
were treated with roscovitine, a Cdk2/Cdk1 inhibitor. After 6 hours of roscovitine treatment, pT187-p27 levels 
were highly reduced compared with that of untreated cells (Fig. 8d). Altogether, the results are consistent with 
the hypothesis that the phosphorylation is carried out by Cdk1. To corroborate this, Cdk1 immunocomplexes 
prepared from TKO and TKO-Myc MEFs were subjected to in vitro kinase assays using His-p27 as substrate. 
The results showed that overexpression of Myc (TKO-Myc cells) induced Cdk1-mediated p27 phosphorylation 
(Fig. 8e). To determine the cyclins involved in the regulation of Cdk1-mediated p27 phosphorylation in TKO-Myc 
cells we performed immunoprecipitations with antibodies for cyclin A2, cyclin B1and cyclin E as well as Cdk1 
(Supplementary Fig. S6b) and determined their kinase activity on p27. Immunocomplexes of both cyclin A2 and 
cyclin B1 contained Cdk1 in TKO-Myc MEFs and were able to phosphorylate p27 in vitro. Immunoprecipitated 
cyclin E from TKO-Myc MEFs did not contain Cdk1 and consistently, showed no kinase activity (Fig. 9a). In 
order to determine which of the complexes (cyclin A2-Cdk1 or cyclinB1-Cdk1) was more active over p27 we 
carried out kinase assays with three different dilutions of the immunoprecipitated complexes (Fig. 9a). The kinase 
assays demonstrated that cyclin A2 and cyclin B1 immunocomplexes yielded similar p27 phosphorylation levels 
in vitro, although the amount of Cdk1 that co-immunoprecipitated with cyclin A2 was lower than did with cyclin 
B1. This result suggested that cyclin A2-Cdk1 complexes were more efficient in phosphorylating p27 at the Thr-
187 than cyclin B1-Cdk1 complexes. However, complexes obtained by immunoprecipitating Cdk1 yielded p27 
Figure 5. p27 is phosphorylated at the Thr-187 in Ccne−/− MEFs. (a) In vitro kinase assays of Cdk2 and 
Cdk1 from Ccne−/− MEFs using His-p27 as substrate. Immunoprecipitated Cdk2 and Cdk1 are shown. (b) 
Cdk1 from Ccne−/− Lv141 or Ccne−/− Myc MEFs was immunoprecipitated and assayed in vitro over p27. (c) 
Cyclin A2 from Ccne−/− Lv141 or Ccne−/− Myc MEFs was immunoprecipitated and assayed in vitro over p27. 
Immunocomplexes were treated with 10 µM purvalanol A (Purv A) or vehicle (DMSO) in the kinase assays 
when indicated. Signal densitometry quantification of the kinase assays are shown below each lane. Kinase 
buffer with His-p27 was used as negative control (No IP) and unspecific IgG was used as negative control for the 
specificity of the antibody used for immunoprecipitation.
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phosphorylation in a much lesser extent when compared to cyclin A2 and cyclin B1 immunocomplexes, being 
Cdk1 amounts much higher. To explain these results, we hypothesized that only a small fraction of the immu-
noprecipitated Cdk1 was complexed with cyclin A2 or cyclin B1, while the rest was unbound and thus, inactive 
Cdk1. To test this hypothesis, total protein lysates from Cdk2−/− Myc MEFs and their control Cdk2−/− Lv141 
MEFs were separated by gel filtration chromatography. The fractions containing Cdk1 were identified by western 
blot and the results showed that Cdk1 is distributed in high-molecular mass complexes corresponding to a molec-
ular mass of about 80 kDa (Fig. 9b, fractions 11 to 14), and free form corresponding to a molecular mass of about 
35 kDa, i.e., the molecular mass of Cdk1 (Fig. 9b, fractions 18 to 21). Cyclins B1 and A2 coeluted with Cdk1 in 
the high molecular mass fractions, which likely contain the cyclin-cdk complexes, but the amount of Cdk1 in the 
cyclin fraction is much lower than the free Cdk1 (Fig. 9b). We hypothesized that most of the Cdk1 immunopre-
cipitated was inactive because it was not bound to any cyclin. The fractions containing the free form of Cdk1 and 
the ones containing the high-molecular mass complexes of Cdk1, respectively, were pooled and Cdk1 was immu-
noprecipitated followed by in vitro kinase assay. These results showed that free-from Cdk1 was inactive while the 
Cdk1 from the high-molecular mass complexes showed kinase activity over p27 in vitro (Fig. 9c). These results 
revealed that most of the Cdk1 was unbound to cyclins, but as expected, only the cyclin-bound Cdk1 showed 
kinase activity on p27. Thus, we can attribute the low kinase activity of Cdk1 in Fig. 9 to a much higher ratio of 
inactive versus active Cdk1 present in the immunocomplexes obtained. Based on these data, we conclude that 
Myc can trigger p27 phosphorylation through the induction of Cdk1 activity independently of Cdk2 and Cdk4/6.
The synthetic lethality between Myc and Cdk1 has previously shown based on the selectivity of purvalanol 
against Cdk138,39. We wanted to corroborate this in cells deficient in Cdk2, Cdk4 and Cdk6, as purvalanol A will 
target specifically Cdk1 in these cells. To do so, we compared the effect of purvalanol A on TKO and TKO-Myc 
cells. The results showed that purvalanol A inhibited more efficiently the growth of cells overexpressing Myc 
(Fig. 9d). TKO-Myc cells exposed to purvalanol A treatment showed a dramatic increase in annexin V binding 
Figure 6. Cyclin A2 is not essential for Cdk1 to phosphorylate p27 in vitro. (a) In vitro kinase assay of cyclin 
A2 complexes from Cdk2−/− Lv141 and Cdk2−/− Myc MEFs using His-p27 as substrate. (b) Total lysates of 
knocked down cyclin A2 Cdk2−/− Lv141 and Cdk2−/− Myc MEFs assayed by western blot. Cyclin A2, cyclin 
B1, Cdk1 and Myc levels are shown. Actin levels were used as loading control. (c) In vitro kinase assay of 
Cdk1 complexes from Cdk2−/− Lv141 and Cdk2−/− Myc MEFs with knocked down cyclin A2 expression. The 
amount of immunoprecipitated Cdk1 is shown. (d) Left panel: In vitro kinase assay of cyclin B1 complexes from 
Cdk2−/− Lv141 and Cdk2−/− Myc MEFs with knocked down cyclin A2 expression. Right panel: Densitometry 
quantification of the relative cyclin B1 kinase activity. Error bars represent ± SD of the quantification of 
two independent experiments. Immunocomplexes were treated with 10 µM purvalanol A (Purv A) or 
vehicle (DMSO) in the kinase assays when indicated. Kinase buffer with His-p27 was used as negative 
control (No IP) and unspecific IgG was used as negative control for the specificity of the antibody used for 
immunoprecipitation.
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compared with TKO control cells, indicating that Myc overexpression makes these cells prone to cell death in 
response to Cdk1 inhibition (Fig. 9e, Supplementary Fig. S7). The results corroborate the lethal synthesis between 
Cdk1 and Myc in this model.
Cdk1-conditionally knock out cells verify that p27 phosphorylation can be mediated by cyclin 
B1-Cdk1 and induced by Myc. As described in the Introduction, Cdk1 has been reported as the only 
indispensable Cdk in animal cells, i.e., no other interphase Cdk is capable of supplying Cdk1 to accomplish 
Figure 7. Myc induces proliferation and the expression of cell cycle-related genes in Cdk2−/−; Cdk4−/− and 
Cdk6−/− (TKO) MEFs. (a) Proliferation curves of TKO and TKO-Myc MEFs. Error bars represent ± SD of 
three independent experiments. (b) Cell cycle distribution in TKO and TKO-Myc MEFs. Data represent the 
average of independent experiments with similar results. (c) mRNA expression of Ccna2, Ccnb1, Ccne2 and 
Cdk1 analyzed by RT-PCR of TKO MEFs and TKO-Myc MEFs. mRNA expression normalized against β-actin 
levels. Error bars represent ± SD of two independent experiments. (d) Cyclin B1, cyclin A2, Cdk1 and Myc 
protein levels analyzed by western blot in TKO and TKO-Myc MEFs. Actin levels are used as loading control. 
(e) mRNA expression of Ccne2, Ccna2 and Ccnb1 at the indicated periods of time after serum stimulation 
in serum-starved TKO and TKO-Myc MEFs determined by RT-PCR. mRNA expression normalized against 
β-actin levels. Error bars represent ± SD of three independent experiments. Statistical analysis: T.test: *p < 0.1; 
**p < 0.05; ***p < 0.01. (f) TKO-Myc MEFs with downregulated Myc expression by shRNA transduction for 
MYC gene. Myc and phospho-H3 levels are shown. Actin levels are used as loading control. (g) Proliferation 
curve of TKO-Myc MEFs compared with Myc knocked down TKO Myc MEFs by shRNA transduction. Error 
bars represent ± SD of two independent experiments. (h) mRNA expression of Ccna2, Ccnb1, Ccne2 and Cdk1 
mRNA analyzed by RT-PCR of TKO-Myc MEFs and TKO-Myc transduced with shMyc lentivirus. mRNA 
expression normalized against β-actin levels. Error bars represent ± SD of two independent experiments.
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an entire cell division7. To confirm the Cdk1-mediated phosphorylation of p27 at the Thr-187, we generated 
a Cdk1-conditional knock out MEF cell line (Cdk1lox/lox MEFs) and its respective control (Cdk1+/lox MEFs). 
Treatment of the Cdk1lox/lox cell line with 4HT leads to Cdk1 knock out, whereas the Cdk1+/l°x cell line shows 
normal Cdk1 expression (Fig. 10A). We first performed kinetics and found that after 72 hours of 4HT treatment, 
Cdk1 protein levels were almost undetectable, while control cells or cells treated with the vehicle (DMSO) did not 
show any change in Cdk1 levels (Fig. 10a). No major changes in Cdk2, cyclin A2 and B1 expression were found 
in Cdk1-depleted cells (Fig. 10a).
Next, the effect of Myc overexpression over Cdk1-mediated p27 phosphorylation was analyzed. For this 
purpose, cells were transiently transduced with a Myc-IRES-GFP construct or the corresponding empty vector 
(Lv141). Myc overexpression after 72 hours was confirmed by western blot and was accompanied with increased 
expression of cyclins A2 and B1 (Fig. 10b). We assayed the kinase activity on p27 of cyclin B1 immunoprecipitates 
from Cdk1lox/lox MEFs and Cdk1+/lox MEFs. In this immunoprecipitates, the kinase reaction should be carried out 
by cyclin B1-Cdk1 dimers, as cyclin B1-Cdk2 complexes have been reported but seem to be inactive or less effi-
cient in the phosphorylation of RXL-containing substrates such as p2740. p27 phosphorylation was determined 
after 72 hours of 4HT or vehicle treatment and Myc-IRES-GFP transduction. Cyclin B1 complexes were able to 
phosphorylate p27 in vitro, in agreement with our previous results and those from others29 and its activity was 
increased upon Myc overexpression (Fig. 10c). Cdk1 depletion resulted in totally abolition of cyclin B1-associated 
kinase activity and Myc was not able to overcome it (Fig. 10c). This result demonstrates that cyclin B1-associated 
kinase activity over p27 is exclusively mediated through Cdk1, discarding the possibility that other Cdk could 
substitute for Cdk1 loss. Upon Myc overexpression, cyclin B1 complexes obtained from Cdk1+/lox MEFs yielded 
Figure 8. Myc induces p27 downregulation and phosphorylation in TKO MEFs. (a) Protein extracts from 
TKO, TKO-Myc and shMyc TKO-Myc MEFs showing total Cdk activity measured by western blot using a 
phospho-specific antibody for the consensus sequence recognized and phosphorylated by Cdks. Actin levels 
are used as loading control. (b) mRNA expression of Skp2 in TKO, TKO-Myc and shMyc-TKO-Myc MEFs. 
mRNA expression is normalized to β actin levels. Error bars represent ± SD of two independent experiments. 
(c) Protein levels of Myc, p27 and Skp2 from TKO and TKO-Myc MEFs are shown. Myc and actin signals of 
the upper blot are the same than in Fig. 7d. (d) pT187-p27, total p27, Myc and Cdk1 levels analysed in protein 
extracts from YFP-p27 transfected TKO-Myc MEFs and treated with 10 µM roscovitine for 6 h. Actin levels 
were used as loading control. (e) In vitro kinase assays of Cdk1 immunocomplexes from TKO and TKO-Myc 
MEFs on His-p27 as substrate. Immunocomplexes were treated with 10 µM purvalanol A (Purv A) or vehicle 
(DMSO) in the kinase assays when indicated. Signal densitometry quantification of the kinase assays are 
shown below each lane. Unspecific IgG was used as negative control for the specificity of the antibody used for 
immunoprecipitation.
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higher pT187-p27 levels while Myc overexpression did not make any difference in 4HT-treated cells (Fig. 10c). 
Levels of immunoprecipitated cyclin B1 are shown in Supplementary Fig. S8. We also tested the effect of Myc 
overexpression on the kinase activity associated to cyclin A2 after Cdk1 ablation. The results showed that Myc 
overexpression led to higher cyclin A2-associated kinase activity on p27 in Cdk1-expressing cells (Fig. 10d). 
Figure 9. Cyclin A2 and cyclin B1 associated to Cdk1 phosphorylate p27 at the Thr-187 in MEFs lacking 
Cdk2. (a) In vitro kinase assays of cyclin A2, cyclin B1, cyclin E2 and Cdk1 complexes from TKO-Myc MEFs 
using His-p27 as substrate. The immunoprecipitated complexes were undiluted or diluted 1:3 and 1:9 before 
the kinase assay as indicated. Quantification of the relative kinase activity of each complex is represented. (b) 
Protein extracts from Cdk2−/− Lv141 and Cdk2−/− Myc MEFs were separated by gel-filtration chromatography 
and distribution of cyclin A2, cyclin B1 and Cdk1 was analyzed by western blot (*indicates an unspecific band). 
(c) Cdk1 immunoprecipitation from fractions corresponding to free Cdk1 (18–21) and complexed cyclin A2/
B1-Cdk1 (11–14) in vitro kinase assays on His-p27 as substrate. Relative levels of pT187-p27 vs p27 determined 
by signal densitometry are shown below each lane. (d) Proliferation rates of TKO and TKO-Myc MEFs 
measured by Crystal Violet staining after treatment with 10 µM of purvalanol A for 24, 48 and 72 hours. Error 
bars represent ± SD of three independent experiments. (e) Apoptotic rates of TKO and TKO Myc MEFs after 
treatment with 5 µM of Purvalanol A for 24 hours. Error bars represent ± SD of three independent experiments. 
Statistical analysis: T.test: *p < 0.1; **p < 0.05.
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Moreover, depletion of Cdk1 expression resulted in enhanced cyclin A2-associated kinase activity, which was also 
increased upon Myc overexpression (Fig. 10d). This could be explained by a potencial increase in cyclin A2-Cdk2 
complexes in the absence of Cdk1, suggesting that Cdk2 is more efficient in mediating p27 phosphorylation than 
Cdk1. The overexpression of Myc three days after lentiviral transduction and the ablation of Cdk1 in this experi-
ment were assessed by western blot (Fig. 10e).
Discussion
Our data unveils a novel mechanism by which Myc contributes to p27 degradation. It has been previously shown 
that Skp2 is a Myc target gene and that, in order to be recognized by the ubiquitin ligase E3 complex SCFSKP2, 
p27 must be phosphorylated in Thr-187. This phosphorylation was previously reported to be carried out in vitro 
mainly by the heterocomplex cyclin E-Cdk230,33. However, in the present work we have confirmed that it can also 
be mediated by Cdk1.
Which is the major cyclin that regulates Cdk1-mediated p27 phosphorylation in response to Myc overex-
pression? We show here that Myc can induce expression of cyclins A, B and E. Among them, only cyclin A2 
and cyclin B1 would activate Cdk1 to phosphorylate p27 in the absence of Cdk2. Taken together, our results in 
MEFs suggest that both cyclin A2 and cyclin B1 are contributing to p27 phosphorylation through Cdk1. This is 
Figure 10. Conditional knock out of Cdk1 totally abolishes cyclin B1-dependent phosphorylation of p27. 
(a) Protein extracts from Cdk1 conditional knock out MEFs and controls treated with 0.6 μM 4HT or vehicle 
(DMSO) for different periods of time. Expression of cyclin A2, cyclin B1, Cdk1 and Cdk2 are shown. Actin 
levels were measured as loading control. (b) Cdk1lox/lox MEFs transduced with a MYC-IRES-GFP construct or 
the corresponding empty vector. Myc overexpression assayed by western blot along with cyclin B1 and cyclin 
A2 levels. (c) In vitro kinase assay of cyclin B1 immunocomplexes on His-p27 in Cdk1lox/lox and control Cdk1+/lox 
treated with 4HT for 72 hours using p27 as substrate. (d) In vitro kinase assay of immunoprecipitated cyclin 
A2 from Cdk1lox/lox MEFs transduced with a Myc-IRES-GFP construct or the corresponding empty vector 
and treated with 4HT for 72 hours. (e) Expression of Myc and Cdk1 in Cdk1lox/lox MEFs transduced with a 
Myc-IRES-GFP construct and treated with 0.6 μM 4HT or DMSO for 72 hours. Actin levels were determined 
as loading control. Signal densitometry quantification of the kinase assays are shown below each lane. Kinase 
buffer with His-p27 was used as negative control (No IP) and unspecific IgG was used as negative control for the 
specificity of the antibody used for immunoprecipitation.
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consistent with previous reports describing that cyclin B1‐Cdk1 can phosphorylate p27 in vitro29,36 while this is 
the first evidence of cyclin A2-Cdk1-mediated p27 phosphorylation. Moreover, this interaction would be more 
relevant in terms of p27 recognition by the ligase complex SCFSKP2, as cyclin A2 (but not cyclins E or B) has been 
described to be essential for this interaction41. Nevertheless, when we compared the activity of cyclin A2 or cyclin 
B1 immunocomplexes with that of Cdk1 immunocomplexes in TKO cells, we found that complexes obtained by 
pulling-down Cdk1 were much less efficient in phosphorylating p27 than the others. This can be explained if most 
of the Cdk1 is unbound to cyclins, and thus inactive, and this is indeed the case as demonstrated by gel filtration 
assays. Finally, the Myc-Cdk1-p27 axis is not only operative in mouse fibroblasts but also confirmed in human 
myeloid leukemia cells with conditional expression of Myc and p27.
Taken together, the results shown in this work indicate that Myc induces the phosphorylation of p27 at Thr-
187 through the activation of not only Cdk2 (as previously described) but also through Cdk1. Cyclin B1 has Cdk1 
as the unique partner capable of phosphorylating p27 in agreement with the fact that Cdk1 is being reported to 
show functions that cannot be compensated by any other7. Furthermore, the kinase activity on p27 associated 
to cyclin A2 increased after Myc overexpression. In this case, p27 phosphorylation would be carried out by the 
combination of Cdk1 and Cdk2 activities in control cells, as they both are cyclin A2 partners. However, the com-
plete ablation of Cdk1 would increase the amount of Cdk2 bound to cyclin A2 and this would lead to higher p27 
phosphorylation levels, suggesting that Cdk2 is more efficient in phosphorylating p27 at the Thr-187 than Cdk1. 
This result agrees with the ones obtained in Fig. 1, in which the efficiency of Cdk2-mediated p27 phosphorylation 
is much higher than that of Cdk1.
In summary, Myc would promote p27 degradation through a triple effect: (i) the induction of Skp2 expres-
sion, which is the major pathway for p27 ubiquitination and degradation; (ii) the activation of Cdk2 via the 
upregulation of its cyclin partners and (iii) the activation of Cdk1, a mechanism previously unreported. These 
mechanisms are summarized in Fig. 11a. In tumor cells the high levels of Myc, or the induction of Myc levels 
by mitogenic stimuli in normal cells, would lead to p27 phosphorylation, ubiquitination and degradation. This 
pathway along the cell cycle is schematized in Fig. 11b. Synthetic lethality has been proposed as an alternative 
antitumoral therapy when the oncogene involved is not easily druggable. This would be the case of Myc42. The 
chemical inhibition of Cdk1 and Cdk2 has been previously identified to be synthetic-lethal with Myc or N-Myc 
overexpression38,39,43. As Myc’s pro-apoptotic effect under suboptimal conditions is well known44, it is conceivable 
that inhibition of Cdk1 would result in elevated p27 and thus an enhanced apoptotic effect of Myc. In conclusion, 
the results described here are relevant due to (i) the opposite correlation between Myc and p27 levels found in 
many human tumors and its correlation with poor disease outcome45,46 and (ii) the proposed new Myc-Cdk1 
interaction involving p27 that could account for the still poorly understood mechanism that relies under the 
described synthetic lethality between Myc overexpression and Cdk1 pharmacological inhibition.
Figure 11. (a) Schematic model of the Myc pathways leading to p27 degradation. These are (i) the induction 
of Cdk2 activity; (ii) the induction of Skp2 and (iii) and the induction of Cdk1 activity, shown in this work. 
(b) Model of the effect of Myc on p27 degradation through p27 phosphorylation by Cdk1 and Skp2 induction. 
p27 can also be phosphorylated by Cdk2, not included in the figure.
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Materials and Methods
Cell culture. Mouse embryonic fibroblast (MEFs) cell lines were prepared from E12.5 embryos (from 
129/svJXC57BL/6 J mice) following standard protocols47, in accordance with Spanish Animal Protection Law 
RD53/2013 and the European Directive ECC/566/2015, and with approval from the Institutional Animal Care 
and Use Committee (code 032-03) of the Centro Nacional de Investigaciones Oncológicas (CNIO). HeLa and 
HEK293T cell lines were from ATTC. MEFs, HeLa and HEK293T were grown in DMEM (Lonza). Kp27MER cell 
line derive from K562 (from ATCC) and was generated in the laboratory of the authors as described19 and was 
grown in RPMI (Lonza). All media were supplemented with 10% (v/v) fetal bovine serum (Lonza), 150 µg/ml 
gentamycin and 2 µg/ml ciprofloxacin, and additional antibiotics depending on the cell line, as described below. 
The following MEFs were transduced with the lentiviral vector Lv141-GFP-Myc or its respective Lv141-GFP 
empty vector to generate stably or transiently Myc-overexpressing cells: Cdk2−/− MEFs (derived from Cdk2−/− 
mice-G418 resistant); TKO MEFs (derived from Ck2−/−;Cdk4−/−;Cdk6−/− mice-G418/puromycin/hygromycin 
resistant); Ccne−/− MEFs (derived from Ccne1/2−/− mice); Cdk1lox/lox MEFs (derived from Cdk1lox/lox mice) and 
Cdk1+/lox MEFs (derived from Cdk1+/lox mice). The following stably transfected or transduced cells were main-
tained in presence of the appropriate antibiotics: Cdk2−/− MER MEFs were grown with 3 µg/ml of puromycin; 
pLKO-Cdk2−/− MEFs and shCyclin A2-Cdk2−/− MEFs were grown with puromycin 6 µg/ml; Kp27MER19 cells 
were grown with puromycin (0.5 µg/ml) and G418 (250 µg/ml). Cells were grown in normoxia in a humidified 
atmosphere at 37 °C and 5% CO2 except for TKO MEFs that were grown under hypoxia (3.5% O2). The plasmids 
used for transfection and lentiviral production are described in the Supplementary Table S1.
Generation of Cdk1lox mice. MEFs conditionally expressing Cdk1 were generated using the lox 
system. The targeting vector for generating the murine Cdk1lox allele was constructed by Gene Bridges 
(Heidelberg, Germany). In brief, the genomic region encoding Cdk1 was cloned from the BAC RP23-178K6. 
The BAC-containing fragments of interest were then subcloned into a minimal pMV vector. The insertion of 
FRT-PGK-gb2-neo/km-FRT-loxP cassette as well as the distal loxP site into the Cdk1 locus was performed by 
one Red/ET triple recombination step and verified by sequencing. The linearized targeting vector was electro-
porated into mouse embryonic stem cells (ES) by the Transgenic Unit of the CNIO (Madrid, Spain). ES cell 
clones having undergone proper homologous recombination were identified by southern blot. Single cell sus-
pensions of two independent ES clones (ESSD12.188 and ESSD12.193) were microinjected into FVB donor blas-
tocysts and implanted into hormonally induced pregnant C57BL/6 J females. Two male founder chimeras were 
utilized to generate germ-line transmission and crossed to a Flp-recombinase expressing strain to eliminate the 
PGK-gb2-neo selectable cassette. In the resulting conditional allele, the loxP sites flank exon 2 in the Cdk1 recom-
binant locus. These mice were crossed with mice Cre-ER+/+ to generate Cdk1lox/lox; CreER+/+ mice. MEFs were 
prepared form E13.5 embryos. The CreER allele was generated as described48.
Proliferation assays, treatments and transfections. For proliferation assays, 2.5 × 104 cells/well were 
seeded in six-well plates, harvested when indicated and counted in a NucleoCounter apparatus (Chemometec). 
Alternatively, cell proliferation was measured by crystal violet staining. For quantification, crystal violet was 
solubilized with acetic acid measured at 595 nm absorbance as described49. Cell synchronization for cell cycle 
studies was carried out as follows: cells at a 60% confluence were washed with PBS and serum starved. After two 
days, media was removed, and fresh media containing 50 µM hydroxyurea was added and further incubated for 
12 hours. Then, cells were washed with PBS and stimulated with DMEM supplemented with 10% FBS. Cells were 
harvested for RNA preparation and cell cycle assay when indicated. For cell cycle assay, one million of cells were 
resuspended with 3 mM EDTA-PBS and fixed with cold absolute ethanol overnight. Then, cells were incubated 
with Hoechst (5 µg/mL) for 30 min at 37 °C (protected from light) followed by cell cycle profile measurement 
in a MACSQuant VYB (Miltenyi Biotec). Results were analyzed with Flow Logic software (Miltenyi Biotec). 
Drugs were added when indicated at the following concentrations: 0.6 or 0.2 µM 4HT (4-hydroxi-tamoxifen) 
(Sigma-Aldrich) for MEFs or Kp27MER respectively, 30 µg/mL of cycloheximide (Sigma-Aldrich), 10 µM of ros-
covitine (Sigma-Aldrich), 50 µM of Zn2SO4 and 10 µM purvalanol A (Sigma-Aldrich). Transfection of MEFs was 
performed using PEI reagent (Polysciences, Inc). Briefly, PEI and DNA were mixed in free serum DMEM in a 
ratio 2.5:1 PEI:DNA (µg), vortexed and incubated 10–30 min RT. Culture media was replaced by half the amount 
of serum-free media and mixture of PEI + DNA was added to cells at 60–70% of confluence. After 12 hours of 
transfection mixture of PEI + DNA was removed, and cells supplemented with complete media. The list of con-
structs used in this work can be found in the online Supplementary Material (Supplementary Table S1).
Lentivirus production and cell transduction. HEK293T cells were transfected with PEI as previously 
described to generate lentiviral particles. Mixture of packaging plasmids (pCMV-VSV-G and psPAX2 from 
Addgene) and construct of interest was performed in a ratio of 1:3:4 (VSV-G:psPAX2: lentiviral construct). 
Lentiviral particles-containing supernatants were collected and stored at 4 °C in two rounds (48 and 72 hours after 
transfection). Supernatants were clarified at 1500 rpm for 10 minutes and filtered. For lentivirus concentration, 
clarified supernatants were mixed with PEG8000 (final concentration of 15% PEG8000), homogenized by inver-
sion and led at 4 °C for 24–72 h. The mixture was centrifuged at 1500xg for 30 minutes at 4 °C, and the pellet with 
lentivirus was dissolved in small volumes of serum-free media and stored at −80 °C. For lentivirus tittering, HeLa 
cells were infected with increasing amounts of concentrated lentiviral particles (usually from 0.1 to 10 µL) and 
selected with puromycin. A multiplicity of infection ≥5 was used to transduce MEFs. For infection, the cells were 
pelleted and resuspended in the corresponding volume of lentivirus with 8 µg/mL of polybrene. The mixture of 
cells and lentivirus was incubated at 37 °C for 1 hour, resuspended every 10 minutes and plated in half of the vol-
ume for the corresponding plate in serum-containing media. After 12–18 hours, the same volume of media was 
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added to reach the final volume of the corresponding plate and 48 hours after transduction lentivirus-containing 
media was replaced by fresh media and puromycin selection when indicated.
Annexin V binding assay. Cells were seeded in a 60% confluence and 12 h later treated with 5 µM pur-
valanol A for 24 h. Cells were harvested, washed twice with PBS-3 mM EDTA, resuspended in 100 µL of 
Binding Buffer (10 mM Hepes/NaOH, 140 mM NaCl and 2.5 mM CaCl2, pH 7.4) and 2 µL FITC Annexin V (BD 
Bioscience) and incubated for 30 min at 4 °C. Cells were washed twice with PBS and resuspended in 250 µL of 
PBS. Annexin V binding was assayed in MACSQuant VYB (Miltenyi Biotec) and the results were analyzed with 
Flow Logic software (Miltenyi Biotec).
mRNA expression analysis by qPCR. RNA extraction was carried out using Tri Reagent (Sigma-Aldrich). 
Roughly, 5 × 105 cells were lysed in 0.5 mL of Tri Reagent, 0.1 mL of chloroform was added and gen-
tly mixed. The mixture was incubated at RT for 2 minutes and centrifuged at 13000 rpm for 15 min. Nucleic 
acid containing aqueous phase was transferred to a new 1.5 mL tube. For RNA precipitation, 0.25 mL of iso-
propanol was added, mixed by inversion, incubated at RT for 10 minutes and centrifuged for 15 minutes at 
13,000 rpm 4 °C. Supernatant was discarded and 0.5 mL of 70% ethanol added. The RNA containing pellet 
was mixed by vortexing and centrifuged for 5 minutes at 7500 rpm 4 °C. Supernatant was discarded, RNA air 
dried and resuspended in RNAse free water. RNA concentration was determined by using a NanoDrop and 
200 ng were resolved in an agarose gel to check the integrity of the RNA. For cDNA conversion, the iScript 
cDNA Synthesis Kit from Bio-Rad was used following manufacturer’s protocol for 1 µg of RNA as tem-
plate. SYBR Select Master Mix from Applied Biosystems was used to amplify cDNA in a CFX Connect 
Real-Time PCR Detection System from Bio-Rad. qPCRs were analyzed with the CFX Manager software. 
The mRNA expression of genes of interest was normalized to β-actin mRNA expression. Murine primer 
sequences used (forward and reverse primers in 5′→3′ direction) Cdk1: CGGCGAGTTCTTCACAGAG and 
AACCGGAGTGGAGTAACGAG; Cdk4:GGCCTGTGTCTATGGTCTGG and TTCAGCCACGGGTTCATATC; 
Ccna2:GCCAGCTGAGCTTAAAGAAAC and AACGTTCACTGGCTTGTCTTC; Ccnb1: GACGTAGA 
CGCAGATGATGG and GCCAGTCAATGAGGATAGCTC; Ccne2: GCATTCTGACCTGGAACCAC and 
GGAAGCAATGAACAATGAGG; Skp2: AATCTGCACCCAGACGTGAC and TGGAGCACTCGGACAGAATC; 
bactin: AGACTTCGAGCAGGAGATGG and AGTTTCATGGATGCCACAGG.
Protein levels analysis by western blot. Roughly, 100 µl of 1% NP40 lysis buffer (50 mM Tris-HCl pH 8, 
150 mM NaCl, 1 mM EDTA, 10 mM NaF, 1% NP40 (v/v), 0.1% SDS; protease (Calbiochem) and phosphatase 
(Sigma-Aldrich) inhibitors added immediately before use) were used to lyse 5 × 105 cells. All the steps were per-
formed at 4 °C. Adherent material was washed once with cold PBS and directly lysed in the plate using a scrapper 
and protein extracts were collected in a 1.5 mL tube. Suspension cells were pelleted, washed once with cold PBS 
and incubated in lysis buffer for 30 min on ice, mixing them every 10 min by pipetting. Protein samples were 
sonicated (10 cycles in a Bioruptor Plus Sonicator device) and finally clarify by centrifugation at 14,000 rpm 
for 20 min at 4 °C. The supernatant was transferred to a new tube and kept frozen until used. Protein quantifi-
cation was carried out using the Qubit Protein Assay Kit in a Qubit 2.0 Fluorometer. Samples were resolved by 
SDS-PAGE and transferred to a nitrocellulose membrane. Blocking was carried out at room temperature using 
4% BSA in TBS-T for 1 hour. Primary antibodies were used diluted in TBS-T 1%BSA at a final concentration of 
1:1000 unless indicated. IRDye800 or lRDye680 (LiCor Biosciences) secondary antibodies or Trueblot anti-rabbit 
or anti-mouse IgG DyLight 800 secondary antibodies (Rockland) were used. Signals were recorded with and 
Odyssey Infrared Imaging Scanner (LiCor Biosciences). Quantification and densitometry analysis were carried 
out using the ImageJ software. Primary antibodies: cdc2 p34-(17) (Santa Cruz Biotechnology, sc-54, monoclonal 
antibody used for immunoprecipitations and western blots); cdc2 p34 C19 polyclonal (sc-954, used for western 
blots); cdk2 M2 (sc-163); cdk4 C22 (sc-260); cyclin A2 H432 (sc-239); cyclin B1 GNS1 (sc-245, used 1:500 in 
western blots); cyclin E H111 (sc-248, used 1:500); His-probe H15 (sc-813); myc N262 (sc-764, used 1:2000 
5% BSA); p27 C19 (sc-528); p27 C19 (sc-528-G); skp2 p45 H435 (sc-7164); actin I19 (sc-1616); phospho-Cdk 
substrate motif (Cell Signaling, 9477), Phospho-Thr187 p27 (Invitrogen 71-7700, used 1:1000 in western blots); 
phospho-retinoblastoma (Ser780) Cell Signaling #9307, used 1:500 in western blots).
immunoprecipitation and in vitro kinase assays. Cell lysis was performed using of non-denaturing 
lysis buffer (50 mM Tri-HCl pH7.5, 150 mM NaCl, 1 mM EDTA, 0.5% NP40; protease (Calbiochem) and phos-
phatase (Sigma-Aldrich) inhibitors added immediately before use). After cell lysis and protein quantification 
as previously indicated, 50 µg of protein extracts were separated for whole cell extract analysis and 500 µg were 
used for each immunoprecipitation. Dynabeads-protein G (Invitrogen) were used to capture protein-antibody 
immunocomplexes. Briefly, Dynabeads (15 µL per IP) were washed twice with washing buffer (50 mM Tris-HCl 
pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.5% NP40), added to the protein extract plus antibody mix and incubated 
overnight at 4 °C with rotation. Next, Dynabeads-protein G-immunocomplexes were collected using a mag-
net DynaMag (Invitrogen), washed four times with washing buffer and resuspended in 30 µL of 2x SDS-PAGE 
loading buffer. Protein-protein interactions were analyzed by western blot as previously described. Normal IgG 
was used as negative control for each immunoprecipitation reaction. Alternatively, 1/3 of Dynabeads-protein 
G-immunocomplexes were used for in vitro kinase assay. They were additionally washed twice with kinase buffer 
(50 mM Hepes-NaOH pH 7.2, 150 mM NaCl, 10 mM MgCl2, 2.5 mM EGTA, 1 mM EDTA, 1 mM DTT, 10% glyc-
erol, 10 mM β-glycerophosphate and 10 mM NaF), resuspended in 30 µL kinase buffer supplemented with 50 µM 
ATP and 1 µg of recombinant His6-p27 (His-p27) protein and incubated for 30 min at 30 °C. The kinase reaction 
was stopped by adding 5xSDS-PAGE loading buffer to the reaction. Samples were boiled and phosphorylation 
of p27 at the Thr-187 was measured by western blot using a phospho-specific antibody anti phospho-Thr187 
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p27 (Invitrogen 71-7700). When indicated, the immunocomplexes were incubated with 10 µM purvalanol A (or 
DMSO as control) in the presence of ATP for 30 min at 30 °C. Afterwards, the His-p27 was added to each reaction, 
mixed, incubated for 30 min at 30 °C and analyzed as described. Normal IgG and kinase buffer supplemented 
with ATP and substrate were used as negative controls for the kinase reaction. The relative kinase activity was 
determined by densitometric quantification of the western blot using the ImageJ software and represented as the 
fraction of pT187-p27 signal relative to total p27.
Gel-filtration chromatography of total protein extracts. 107 cells were lysed as described in 200–
300 µL non-denaturing chromatography lysis buffer (50 mM Hepes-NaOH pH 7.2, 150 mM NaCl, 0.05% Triton 
X-100, 1 mM EDTA, 2.5 mM EGTA, 1 mM DTT, 10% glycerol and 1 mM PMSF (protease inhibitor, Calbiochem) 
and phosphatase (Sigma-Aldrich) inhibitors added immediately before use), incubated on ice for 30 min and 
protein extracts clarified at 14000 rpm for 20 min at 4 °C and transferred to a new tube. 200 µL of protein extracts 
were directly applied onto a Superdex 200 10/300 GLcolumn (GE Healthcare) pre-equilibrated with chromatog-
raphy buffer (50 mM Hepes-NaOH pH 7.2, 150 mM NaCl, 0.05% Triton X-100, 1 mM EDTA, 2.5 mM EGTA, 
1 mM DTT, 10% glycerol and 1 mM PMSF) and subjected to fast-performance liquid chromatography in an Äkta 
purifier apparatus (GE Healthcare) with a flow rate of 0.4 mL/min at 4 °C. The protein complexes eluting from the 
column with different volume retentions according to their molecular size were fractionated in 500 µL fractions. 
40 µL of each collected fraction were mixed with 10 µL of 5X SDS-PAGE loading buffer and analyzed by western 
blot as indicated. Alternatively, the selected fractions containing the protein complexes were mixed and subjected 
to immunoprecipitation and in vitro kinase assay as previously described.
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Supplementary Table S1. List of plasmids used in this work. 
Plasmid Construct Origin 
pEYFP Empty vector containing YFP protein Clontech 
pEYFP-p27 Human p27 fused with YFP Our lab 
pCMV-Bam-HA-EV Empty vector Addgene 
pCMV-cdc2-HA WT Cdk1 wild type gene tagged with HA Addgene 
pCMV-cdc2-HA DN CDK1 D146N gene tagged with HA Addgene 
EX-NEG-Lv141 Lentiviral empty vector Genecopoeia 
EX-Z2845-Lv141-MYC Flag Human Myc tagged with Flag; IRES GFP Genecopoeia 
pLKO.1 control Lentiviral empty vector SigmaMission 
pLKO.1 shMYC TRCN0000039640 Lentiviral shRNA for human MYC gene SigmaMission 
pLKO.1 shMYC TRCN0000039642 Lentiviral shRNA for human MYC gene SigmaMission 
pLKO.1 shMYC TRCN0000039655 Lentiviral shRNA for human MYC gene SigmaMission 
pLKO.1 shCyclin A2 TRCN00000 Lentiviral shRNA for mousecyclin A2 gene SigmaMission 
pCMV-VSV-G VSV-G gene encoding envelope lentiviral protein Addgene 
psPAX2 GAG and POL genes encoding packaging lentiviral proteins Addgene 
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Supplementary Figure S1. Induction of p27 and activation of Myc-ER in Kp27MER cells. 
(a) Protein levels of Myc, Myc-ER, cyclin A2 and p27 of Kp27MER cells upon the indicated 
treatments for 24h hours compared with K562 parental cells. Actin levels were measured as 
loading control. (b) Levels of cyclins E, B1 and A2 after immunoprecipitation from Kp27MER 
treated as indicated for 24 hours. The asterisk marks a previous incubation with anti-cyclin E 
antibody. 
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Supplementary Figure S2. Cycloheximide treatment of Cdk2
-/- 
Lv141 or Cdk2
-/- 
Myc MEFs 
leads to Myc rapid degradation. Protein stability of Myc as control of cycloheximide 
effectivity in Cdk2
-/-
 Lv141 and Cdk2
-/-
 Myc MEFs transfected with a p27-YFP construct 
measured by western blot. Levels of Myc were detected after 0, 0.5, 1 and 3 hours of 
cycloheximide treatment (30 µg/mL). Actin levels were used as loading control.  
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Supplementary Figure S3. Total lysates and immunoprecipitations from Ccne
-/-
 Lv141 
and Ccne
-/- 
Myc MEFs. (a) Protein levels of cyclin A2 and Cdk1 from Ccne
-/-
 Lv141 and Ccne
-
/-
 Myc MEFs transduced with shCyclin A2 lentiviral particles or the corresponding control (Ev). 
Actin levels were used as loading control. (b) Co-immunoprecipitation of cyclin A2 and Cdk1 
in Ccne
-/-
 Lv141 and Ccne
-/- 
Myc MEFs. Unspecific IgG was used as negative control for the 
specificity of the antibody used for immunoprecipitation. 
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Supplementary Figure S4. Efficiency of cyclin A2 knock down in Cdk2
-/-
 MEFs measured 
by its kinase activity over 27. (a) Kinase assay of cyclin A2 immunocomplexes obtained 
from Cdk2
-/-
 Lv141 and Cdk2
-/-
 Myc MEFs transduced with shCyclin A2 lentiviral particles or 
the corresponding control (Ev). (b) Densitometric quantification of the relative cyclin A2 kinase 
activity. Error bars represent ±SD of the quantification of three independent experiments.  
Kinase buffer with His-p27 was used as negative control (No IP) and unspecific IgG was used 
as negative control for the specificity of the antibody used for immunoprecipitation. 
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Supplementary Figure S5. Co-immunoprecipitation of cyclins A2 and B1 with Cdk1 in 
Cdk2
-/- 
MEFs. Immunoprecipitated levels of cyclins A2 and B1 and Cdk1 from Cdk2
-/-
 Lv141 
and Cdk2
-/-
 Myc MEFs. Unspecific IgG was used as negative control for the specificity of the 
antibody used for immunoprecipitation. The asterisk marks cyclin B1 from a previous 
incubation with anti-cyclin B1 antibody. 
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Supplementary Figure S6. Cell cycle profile of TKO and TKO-Myc MEFs and Cdk1 
interaction with cyclins A2 and B1. (a) Distribution of cells among G
1
, S and G
2
 phases of 
the cycle of TKO and TKO-Myc MEFs. DNA content was measured using Hoechst staining by 
flow cytometry. (b) Immunoprecipitated levels of cyclins A2 and B1 and Cdk1 from TKO-Myc 
MEFs. Unspecific IgG was used as negative control for the specificity of the antibody used for 
immunoprecipitation.  L.E, low exposure; H.L., high exposure. The asterisk marks cyclin B1 
from a previous incubation with anti-cyclin B1 antibody. 
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Supplementary Figure S7. Apoptotic assay measured by Annexin V positive cells. 
Original plots of Annexin V positive cells of TKO vs TKO-Myc cells treated with Purvalanol A 
for 24 h measured by flow cytometry. 
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Supplementary Figure S8. Co-immunoprecipitation of cyclins A2 and B1 with Cdk1 and 
Cdk2 in Cdk1
lox/lox
 MEFs. (a) Cyclin B1 and A2 immunoprecipitates from Cdk1
lox/lox
 MEFs 
after treatment with 0.6 µM of 4HT or DMSO for 3 days. Levels of co-immunoprecipitated Cdk1 
and Cdk2 are shown. (b) Myc overexpressing Cdk1lox/lox MEFs or their corresponding control 
cells treated for 3 days with 4HT 0.6 µM. Levels of cyclin B1, Cdk1 and Cdk2 after cyclin B1 
immunoprecipitation are shown. 
 
